Raymond James Financial Inc. Purchases New Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Raymond James Financial Inc. bought a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 54,783 shares of the company's stock, valued at approximately $761,000. Raymond James Financial Inc. owned 0.11% of Tyra Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. US Bancorp DE bought a new position in shares of Tyra Biosciences during the 4th quarter worth $50,000. China Universal Asset Management Co. Ltd. purchased a new position in Tyra Biosciences during the 4th quarter valued at about $149,000. Franklin Resources Inc. bought a new stake in shares of Tyra Biosciences in the 3rd quarter valued at about $278,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Tyra Biosciences in the 3rd quarter worth approximately $333,000. Finally, Rhumbline Advisers boosted its stake in shares of Tyra Biosciences by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock valued at $364,000 after purchasing an additional 1,027 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on TYRA shares. Wedbush restated an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Monday, March 31st. Finally, UBS Group began coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences has a consensus rating of "Buy" and an average price target of $30.83.

Remove Ads

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total value of $65,325.48. Following the sale, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This represents a 0.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 21,998 shares of company stock valued at $344,818 in the last ninety days. Company insiders own 15.40% of the company's stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock traded down $0.37 during midday trading on Thursday, reaching $7.55. The company's stock had a trading volume of 417,970 shares, compared to its average volume of 245,429. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $29.60. The stock has a market capitalization of $400.83 million, a P/E ratio of -4.69 and a beta of 1.19. The stock's 50-day simple moving average is $10.84 and its 200-day simple moving average is $15.27.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.05. As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.